Progyny, Inc. (NASDAQ:PGNY) Receives $27.50 Consensus Price Target from Analysts

Shares of Progyny, Inc. (NASDAQ:PGNY) have been given a consensus rating of “Moderate Buy” by the eleven analysts that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $27.50.

Several brokerages recently issued reports on PGNY. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research note on Monday, December 15th. Canaccord Genuity Group upped their target price on Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research report on Monday, November 17th. KeyCorp raised Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 target price on the stock in a report on Tuesday, November 11th. JPMorgan Chase & Co. boosted their price target on Progyny from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Finally, Barclays assumed coverage on shares of Progyny in a research note on Monday, December 8th. They set an “overweight” rating and a $29.00 price objective on the stock.

Insider Activity at Progyny

In other Progyny news, CFO Mark S. Livingston sold 21,303 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $25.50, for a total value of $543,226.50. Following the sale, the chief financial officer owned 48,358 shares of the company’s stock, valued at approximately $1,233,129. This trade represents a 30.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Peter Anevski purchased 79,500 shares of the firm’s stock in a transaction dated Thursday, November 13th. The stock was acquired at an average price of $24.29 per share, for a total transaction of $1,931,055.00. Following the purchase, the chief executive officer owned 680,251 shares in the company, valued at approximately $16,523,296.79. The trade was a 13.23% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 22,046 shares of company stock worth $561,691 in the last quarter. 9.40% of the stock is currently owned by company insiders.

Institutional Trading of Progyny

Several large investors have recently bought and sold shares of the business. Nordea Investment Management AB raised its stake in shares of Progyny by 0.6% during the second quarter. Nordea Investment Management AB now owns 183,362 shares of the company’s stock valued at $4,052,000 after acquiring an additional 1,140 shares during the last quarter. Cresset Asset Management LLC grew its stake in shares of Progyny by 715.3% in the second quarter. Cresset Asset Management LLC now owns 85,053 shares of the company’s stock worth $1,871,000 after purchasing an additional 74,621 shares during the last quarter. Voya Investment Management LLC increased its holdings in Progyny by 258.2% in the first quarter. Voya Investment Management LLC now owns 185,495 shares of the company’s stock valued at $4,144,000 after purchasing an additional 133,703 shares during the period. Millennium Management LLC increased its holdings in Progyny by 7.5% in the first quarter. Millennium Management LLC now owns 1,302,890 shares of the company’s stock valued at $29,107,000 after purchasing an additional 90,367 shares during the period. Finally, Acadian Asset Management LLC raised its position in Progyny by 243.6% during the 1st quarter. Acadian Asset Management LLC now owns 205,650 shares of the company’s stock worth $4,589,000 after purchasing an additional 145,802 shares during the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Price Performance

Shares of NASDAQ PGNY opened at $26.97 on Friday. Progyny has a one year low of $14.11 and a one year high of $27.76. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of 42.81, a P/E/G ratio of 2.10 and a beta of 0.96. The stock’s fifty day moving average price is $23.21 and its two-hundred day moving average price is $22.60.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.06. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The business had revenue of $313.35 million during the quarter, compared to analysts’ expectations of $299.23 million. During the same quarter in the previous year, the company earned $0.11 EPS. The business’s revenue was up 9.3% on a year-over-year basis. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. On average, equities analysts anticipate that Progyny will post 0.6 earnings per share for the current fiscal year.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.